S&P Futures
4,076.50 -8.25 (-0.20%) Dow Futures
32,548.00 -33.00 (-0.10%) Nasdaq Futures
12,513.25 -47.00 (-0.37%) Russell 2000 Futures
1,832.20 -5.00 (-0.27%) Crude Oil
113.87 +1.47 (+1.31%) Gold
1,808.20 -10.70 (-0.59%)
Athira Pharma, Inc. (ATHA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.67 |
| Open | 8.80 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 8.80 - 9.24 |
| 52 Week Range | 7.56 - 23.64 |
| Volume | |
| Avg. Volume | 292,771 |
| Market Cap | 335.713M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.47 |
| Earnings Date | Aug 15, 2022 - Aug 19, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.83 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ATHA
Related Research
- Athira Pharma, Inc.Daily – Vickers Top Buyers & Sellers for 04/04/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast monthArgus Research
- American City Business Journals
Athira shareholder suspends push for board control days before shareholders' meeting
Athira shareholder Richard Kayne had sent multiple letters to shareholders in recent months slamming the biotech's leadership.
- GlobeNewswire
Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest
Athira Board Unanimously Recommends Shareholders Vote “FOR” its Highly Qualified Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., May 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today issued the following statement in response to Richard A. Kayne’s suspension of his proxy contes
- GlobeNewswire
Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
HGF/MET positive modulators reduce pain-related behaviors in a model of diabetic neuropathyBOTHELL, Wash., May 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the presentation of preclinical data on two small molecule positive modulators of the HGF/MET signaling pathway, ATH-1018 and ATH-1019, at the 2022 Peripheral Nerve So
- ProSomnus® Sleep Technologies to Present Three Posters at SLEEP 2022, the Annual Meeting of the American Academy of Sleep Medicine and the Sleep Research SocietyGlobeNewswire
- Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual MeetingGlobeNewswire
